SavedAdd your journal

Journals / Archives of Clinical and Experimental Medicine / 2020 / Cilt: 5 - Sayı: 2

Impact of status of ER, PR, HER2 and Ki-67 index on axillary lymph node metastasis of breast cancer

Meme kanserinin aksiller metastazlarında ER, PR, HER2 ve Ki-67 indeksinin etkisi

Mikail ÇAKIR
Yıldırım B. DOĞAN
Okan Murat AKTÜRK
Oğuzhan SUNAMAK
Turgut DÖNMEZ
Büşra Ekinci BİÇKİCİ
Fazilet ERÖZGEN
Pages
48–51
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: HER2 positivity, Ki-67 index,>

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Axillary status evaluation and, if present, the number of metastatic lymph nodes is important in staging and adjuvant therapy planning of breast cancer.
📊
Key Findings & Data:Methods: A total of 298 women with unilateral breast cancer operated with axillary lymph node dissection or sentinel lymph node biopsy, were retrospectively analyzed for age, localization, BIRADS category, pathological features, subtypes as Luminal A, Luminal B, HER2 positive, triple negative, Ki-67 index and number of lymph nodes involved.
💡
Conclusion & Impact:Conclusions: HER2 positivity, Ki-67 index,>
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:meme kanseri · aksiller lenf nodu metastazı · hormonal durum

Abstract

Aim: Axillary status evaluation and, if present, the number of metastatic lymph nodes is important in staging and adjuvant therapy planning of breast cancer. A number of clinical and pathological variables were analyzed to detect factors affecting nodal status. Methods: A total of 298 women with unilateral breast cancer operated with axillary lymph node dissection or sentinel lymph node biopsy, were retrospectively analyzed for age, localization, BIRADS category, pathological features, subtypes as Luminal A, Luminal B, HER2 positive, triple negative, Ki-67 index and number of lymph nodes involved. Results: The mean age was 54.7 years. BIRADS 5 was the most detected category in 208 (69.8%) patients. The most common pathological type was invasive ductal carcinoma in 265 patients (88.9%). The most detected tumor grade was grade 2 in 160 (31.2%). Luminal B was the most common subtype and detected in 173 patients (58.1%). Ki-67 indexes were detected between 0-14% in 69 patients (23.3%), between 15-19% in 31patients (10.4%) and above 20% in 198 patients (66.4%). Conclusions: HER2 positivity, Ki-67 index,>

Özet

Amaç: Aksiller lenf nodu metastazı değerlendirmesi ve varsa lenf nodu sayısı meme kanserinin evrelemesi ve adjuvan tedavi planlamasında önemlidir. Amacımız lenf nodu metastazını etkileyen faktörleri saptamak için bir dizi klinik ve patolojik değişkeni araştırmaktır. Yöntemler: Aksiller lenf nodu diseksiyonu veya sentinel lenf nodu biyopsisi ile opere edilen tek taraflı meme kanseri olan 298 kadın hastanın yaş, lokalizasyon, BIRADS kategorisi, patolojik özellikler, Luminal A, Luminal B, HER2 pozitif, tripl negatif subtipleri, Ki-67 indeksi verileri ile metastatik lenf nodu sayısı arasındaki ilişkisi analiz edildi. Bulgular: Yaş ortalaması 54,7 yıl idi. BIRADS 5, 208 (% 69,8) hastada en fazla saptanan kategori idi. En sık görülen patolojik tip 265 hastada (% 88,9) invaziv duktal karsinomdu. En fazla saptanan tümör evresi 2 olup, 160 hastada (% 31,2) tespit edildi. Luminal B en sık görülen subtipti ve 173 (% 58,1) hastada tespit edildi. Ki-67 indeksi 69 hastada (% 23,3) % 0-14, 31 hastada (% 10,4) % 15-19 ve 198 hastada (% 66,4) % 20'nin üzerinde saptandı. Sonuçlar: HER2 pozitifliği, Ki-67 indeksi ve progesteron reseptör negatifliği aksiller lenf nodu metastazını etkileyen en önemli faktörlerdir.

🔖

Cite This Article

ÇAKIR, M., DOĞAN, Y. B., AKTÜRK, O. M., SUNAMAK, O., DÖNMEZ, T., BİÇKİCİ, B. E., ERÖZGEN, F. (2020). Impact of status of ER, PR, HER2 and Ki-67 index on axillary lymph node metastasis of breast cancer. Archives of Clinical and Experimental Medicine, Cilt: 5 - Sayı: 2, 48–51. https://ajindex.com/articles/141524

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. References1. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009
  2. 101(10):736-50. 2. Aitken E, Monzir O. Factors affecting nodal status in invasive breast cancer. A retrospective analysis of 623 patients. The breast Journal. 2010
  3. 16(3):271-8 3. Kayahan M, İdiz UO, Gucin Z, Erözgen F, Memmi N, Müslümanoğlu M. Clinical Significance of Androgen Receptor, CK-5/6, Ki 67 and Molecular subtypes in Breast Cancer. J. Breast Health. 2014
  4. Hui L, Huang T, Lian J, Zhou F, Gao C, Lin Y, et al. Potential prognostic value of clinical characteristics, hormone status and major depressive disorder in breast cancer. Future Oncol. 2017
  5. 13(17):1493-1503. 5. Alco G, Bozdogan A, Selamoglu D, Pilanci KN, Tuzlali S, Ordu C, et al. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncology letters. 2015
  6. Ling Li, Zhang Chen. Factors influencing axillary lymph nodes metastasis in invasive breast cancer. Asian Pac J Cancer Prev.2012
  7. 13(1):251-4. 7. Azizun-Nisa, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR & HER-2/neu (C-erb B 2) Reactivity Pattern with Histologic Grade, Tumor Size and Lymph Node Status in Breast Cancer. Asian Pacific journal of cancer prevention: APJCP. 2008
  8. Gutierrez C, Schiff R. HER2: biology, detection and clinical implications. Arch Pathol Lab Med. 2011
  9. 135(1):55-62. 9. Urruticoechea A, Smith IE, Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 1
  10. 23(28):7212-20. 10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ et al
  11. Panel members. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. 2011. Ann Oncol 2011
  12. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al
  13. Panel members: Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013
  14. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P: Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008
  15. Scottish Intercollegiate Guidelines Network (SGIN) Guideline 84: